Non-Hodgkin Lymphoma

The phase IIb UNITY-NHL clinical trial is exploring the novel drug umbralisib as monotherapy or as part of a doublet or a triplet. The doublet includes ublituximab and the triplet includes ublituximab and bendamustine.

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the role of duvelisib (IPI-145) in the treatment of patients with follicular lymphoma.

Lori Ann Leslie, MD, provides expert insight on the latest developments in the field of follicular lymphoma.

Findings from a small, retrospective study showed that external beam radiation therapy induced an overall response rate of 86% in patients with relapsed/refractory follicular lymphoma.

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses trial updates for patients with follicular lymphoma in the maintenance setting, which were presented at the 2017 ASH Annual Meeting.

A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses the impact of the ZUMA-1 trial for patients with non-Hodgkin Lymphoma (NHL).

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.